THUMPD3

Across TCGA pan-cancer cohorts, THUMPD3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated THUMPD3 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher THUMPD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated THUMPD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

GBM, CCRCC, and PDAC are the cancer types where THUMPD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.550	0.856	<.001	27	view →
CCRCC	DFS	Tertile	All	0.859	0.973	.012	10	view →
PDAC	DFS	Quartile	III,IV	0.954	0.534	.006	8	view →
LUAD	DFS	Median	III,IV	0.900	0.612	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

THUMPD3–GBM (DFS)

Open the GBM breakdown →